Nasal neutrophilia and eosinophilia induced by challenge with platelet activating factor

Tedeschi, A.; Palumbo, Giuseppe A.; Milazzo, N.; Miadonna, A.

doi:10.1016/0091-6749(94)90363-8

Cited by 32 publications

(31 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This release is more rapid and more marked in atopic than in nonatopic subjects. PAF is a potent chemoattractant for eosinophils and neutrophils both in vivo and in vitro [6,25]. A preferential accumulation of eosinophils after intradermal injection of PAF in atopic subjects was demonstrated by HENOCQ and VARGAFTIG [26].…”

Section: Discussionmentioning

confidence: 99%

“…PAF and lyso-PAF are released during the early antigeninduced reaction in the nose of allergic patients [2,34], and both lipids have the capacity to attract and activate neutrophils and eosinophils [6,[25][26][27][28]. Since the cytological picture of the late antigen-induced reaction in human nasal airways is characterized by local accumulation of eosinophils and neutrophils [35,36], one could speculate that PAF contributes to the attraction of these cells and has a role in antigen-induced allergic inflammation in the nose.…”

Section: Discussionmentioning

confidence: 99%

“…PAF, lyso-PAF or saline solution were nebulized into the nose by means of a disposable metered-dose nebulizer calibrated to deliver 100±10 µl per puff. The dose of 500 nmol of PAF was chosen because we have previously observed that this could provoke nasal symptoms and changes in nasal cytology in most subjects [3,6].…”

Section: Nasal Challenge and Nasal Lavage Proceduresmentioning

confidence: 99%

“…Nasal challenge with PAF provokes nasal obstruction with an increase in nasal airway resistances [3], and nasal hyperreactivity [4,5]. Furthermore, nasal neutrophilia and eosinophilia have been observed after challenge with PAF, with a more rapid and more marked response in atopic than in normal subjects [6]. PAF is recognized as a potent bronchoconstrictor in humans [7], but some of its effects in vivo may be mediated indirectly by the release of secondary mediators [8][9][10][11].…”

mentioning

confidence: 99%

See 3 more Smart Citations

Nasal eosinophilia induced by PAF-acether is accompanied by the release of eosinophil cationic protein

1994

View full text Add to dashboard Cite

N Na as sa al l e eo os si in no op ph hi il li ia a i in nd du uc ce ed d b by y P PA AF F--a ac ce et th he er r i is s a ac cc co om mp pa an ni ie ed d b by y t th he e r re el le ea as se e o of f e eo os si in no op ph hi il l c ca at ti io on ni ic c p pr ro ot te ei in n A. Tedeschi, N. Milazzo, A. Miadonna Nasal eosinophilia induced by PAF-acether is accompanied by the release of eosinophil cationic protein. A. Tedeschi, N. Milazzo, A. Miadonna. ERS Journals Ltd 1994. ABSTRACT: It has been demonstrated that platelet-activating factor (PAF)-acether can induce nasal neutrophilia and eosinophilia, with a different degree of responsiveness in atopic and in nonatopic subjects. The aim of this study was to evaluate whether PAF can also induce the release of secondary mediators in the human nose. Ten patients with allergic rhinitis and 10 normal subjects underwent nasal challenge with PAF (500 nmol), lyso-PAF (500 nmol) and saline solution. Nasal lavages were performed before and after challenge to evaluate changes in nasal cytology and release of histamine, immunoreactive leukotriene (iLT) C 4 and eosinophil cationic protein (ECP).PAF caused neutrophilia and eosinophilia, which appeared earlier in atopic than in nonatopic subjects (30 min vs 1 h), and peaked 3 h after challenge in both groups. Lyso-PAF caused mild neutrophilia, which appeared 3 h after challenge in both groups; an increase in eosinophil counts was observed 3 h after challenge in atopic subjects, but not in nonatopic subjects. PAF insufflation caused a significant release of ECP in nasal lavage fluids 30 min and 3h after challenge in atopic subjects, and 3 h after challenge in nonatopic subjects. ECP levels in the nasal lavages collected 30 min and 3 h after challenge with PAF were higher in atopic than in nonatopic subjects. Eosinophil counts correlated with ECP levels in the nasal lavages collected 30 min after PAF challenge in atopic subjects. Nasal challenge with lyso-PAF did not provoke any release of ECP. No significant increase of histamine and iLTC 4 levels in nasal lavages was found after challenge with either PAF or lyso-PAF.These results indicate that PAF-induced nasal eosinophilia is accompanied by ECP release, which appears earlier and is more marked in atopic than in nonatopic subjects.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Nasal Challenge and Nasal Lavage Proceduresmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Nasal eosinophilia induced by PAF-acether is accompanied by the release of eosinophil cationic protein

1994

View full text Add to dashboard Cite

show abstract

“…22 Eo si nop hils are the ma jor inf lam ma tory cells in asthma and a number of stu di es in ves ti ga ted spu tum eo si nop hi li a as a mar ker of lo wer air way inf lam mati on and evaluation of ast hma con trol. 23 Ho we ver, the re is not much in for ma ti on abo ut the im por tance of inf lam ma tory cells in na sal sec re ti ons on the as sess ment of lo wer air way inf lam ma ti on.…”

Section: Fi Gu Rementioning

confidence: 99%

Lower Airway Inflammation in Nonasthmatic Allergic Rhinitis Patients

Alpaydın¹,

Bora²,

Günhan³

et al. 2011

Turkiye Klinikleri J Med Sci

View full text Add to dashboard Cite

A AB BS S T TR RA AC CT T O Ob b j je ec c t ti i v ve e: : Al ler gic rhi ni tis and ast hma ha ve be en con si de red as a sing le air way di se a se sha ring a com mon pat hoph ysi o lo gi cal mec ha nism of air way inf lam ma ti on. We ai med to in ves ti ga te the lo wer airway inf lam ma ti on in al ler gic rhi ni tis pa ti ents without ast hma. M Ma a t te e r ri i a al l a an nd d M Me et t h ho od ds s: : Forty pa ti ents who refer red to our ter ti ary ca re hos pi tal's otor hi no lary ngo logy cli nic and di ag no sed as mo de ra te/se ve re per sis tent al ler gic rhi ni tis ac cor ding to ARI A cri te ri a we re inc lu ded in the study. Af ter eva lu a ti on for the eli gi bi lity for the study, a na sal sme ar was ta ken, and rhi no ma no metry was per for med to me a su re the na sal obs truc ti on on vi sit 1. Twenty-fo ur ho urs la ter from the vi sit 1, pul mo nary func ti ons inc lu ding bronc hi al hype rac ti vity (BHR) we re me a su red on vi sit 2. Twenty-fo ur ho urs la ter from the vi sit 2, spu tum in duc ti on was per for med, and cell dis tri bu ti on of the spu tums was eva lu a ted. R Re e s su ul lt ts s: : Me an age of the 17 ma le and 23 fe ma le pa ti ents was 37 ± 11. Na sal sme ar eo si nop hi li a was studied in 36 of the pa ti ents and fo und positive in 36%. Na sal obs truc ti on was de mons tra ted in 68% of the pa ti ents by rhi no ma no metry. BHR was po si ti ve in 30% of the parti ci pants. The re was not any sta tis ti cal sig ni fi cant re la ti ons hip bet we en na sal eo si nop hi li a and na sal obs truc ti on se ve rity, BHR and in du ced spu tum eo si nop hi li a (p> 0.05). Among the in du ced spu tums which we re of go od qu a lity to be eva lu a ted, 7.5% had an eo si nop hil ra ti o of 2%. Any re la ti ons hip bet we en in duced spu tum eo si nop hil per cen ta ges and FEV1, FEV1/FVC, na sal obs truc ti on se ve rity was not ob ser ved (p> 0.05). Ho we ver, BHR was fo und to be sig ni fi cantly re la ted with FEV1/FVC ra ti o which was >70% thro ugh the who le study po pu la ti on (r= 0.392 p= 0.012). C Co on nc c l lu u s si i o on n: : We co uld not de mons tra te the ex pec ted re la tions hip bet we en na sal and lo wer air way inf lam ma ti on mar kers in our study gro up of al ler gic rhi ni tis pa ti ents. This may be du e to the small num ber of study po pu la ti on and strict exc lu si on of ast hma tic pa ti ents as well as par ti cu larly the dif fi cul ti es in stan dar di za ti on of the in du ced spu tum tech ni qu e. K Ke ey y W Wo or rd ds s: : Rhi ni tis, al ler gic, pe ren ni al; spu tum; inf lam ma ti on me di a tors Ö ÖZ ZE ET T A Am ma aç ç: : Al ler jik ri nit ve as tım, ha va yol la rı nın inf la mas yo nu ile ka rak te ri ze ve or tak bir pa to fiz yo lo jik me ka niz ma yı pay la şan ha va yo lu has ta lık la rı ola rak ka bul edil mek te dir. Ça lış ma mız da, da ha ön ce as tım tanı sı al ma mış olan aler jik ri nit li has ta lar da alt so lu num yo lu inf la mas yo nu nu araş tır ma yı amaç la dık. G Ge e r re eç ç v ve e Y Yö ön ...

show abstract

Platelet activating factor: Have we been missing the forest for the trees?

Antonopoulou

Demopoulos

2022

BioFactors

View full text Add to dashboard Cite

Nasal neutrophilia and eosinophilia induced by challenge with platelet activating factor

Cited by 32 publications

References 31 publications

Nasal eosinophilia induced by PAF-acether is accompanied by the release of eosinophil cationic protein

Nasal eosinophilia induced by PAF-acether is accompanied by the release of eosinophil cationic protein

Lower Airway Inflammation in Nonasthmatic Allergic Rhinitis Patients

Platelet activating factor: Have we been missing the forest for the trees?

Contact Info

Product

Resources

About